ATE497405T1 - Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration - Google Patents

Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration

Info

Publication number
ATE497405T1
ATE497405T1 AT06738066T AT06738066T ATE497405T1 AT E497405 T1 ATE497405 T1 AT E497405T1 AT 06738066 T AT06738066 T AT 06738066T AT 06738066 T AT06738066 T AT 06738066T AT E497405 T1 ATE497405 T1 AT E497405T1
Authority
AT
Austria
Prior art keywords
macular degeneration
coupled receptor
treatment
protein
compositions containing
Prior art date
Application number
AT06738066T
Other languages
English (en)
Inventor
Pascal Deschatelets
Cedric Francois
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE497405T1 publication Critical patent/ATE497405T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Medicinal Preparation (AREA)
AT06738066T 2005-03-11 2006-03-13 Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration ATE497405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66075205P 2005-03-11 2005-03-11
PCT/US2006/008960 WO2006099330A2 (en) 2005-03-11 2006-03-13 Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration

Publications (1)

Publication Number Publication Date
ATE497405T1 true ATE497405T1 (de) 2011-02-15

Family

ID=36992349

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06738066T ATE497405T1 (de) 2005-03-11 2006-03-13 Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration

Country Status (6)

Country Link
US (1) US20090117171A1 (de)
EP (1) EP1861114B1 (de)
AT (1) ATE497405T1 (de)
AU (1) AU2006223108A1 (de)
DE (1) DE602006019948D1 (de)
WO (1) WO2006099330A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
EP2424556A4 (de) * 2009-04-27 2013-07-31 Jerini Ophthalmic Inc Verzögert freigesetzte formulierungen aus peptidomimetischen arzneien und verwendungen davon
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
EP2468295A1 (de) 2010-12-21 2012-06-27 Affiris AG Impfstoffe basierend auf Komplementprotein C5a Peptide
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US10220002B2 (en) * 2011-12-02 2019-03-05 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
JP6184982B2 (ja) 2012-02-02 2017-08-23 エスバテック − ア ノバルティス カンパニー エルエルシー 点眼用抗体含有徐放性製剤
EP3660033B9 (de) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Langwirkende compstatin-analoga sowie verwandte zusammensetzungen und verfahren
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3359555B1 (de) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosierpläne
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
DE60136272D1 (de) * 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
US7595430B2 (en) * 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration

Also Published As

Publication number Publication date
AU2006223108A1 (en) 2006-09-21
EP1861114B1 (de) 2011-02-02
WO2006099330A2 (en) 2006-09-21
DE602006019948D1 (de) 2011-03-17
EP1861114A2 (de) 2007-12-05
US20090117171A1 (en) 2009-05-07
WO2006099330A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
ATE497405T1 (de) Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration
MA29976B1 (fr) Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires.
ATE491444T1 (de) Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
EA201000787A1 (ru) Антигенсвязывающие белки
JP2020537644A5 (de)
EA200701828A1 (ru) Композиции для лечения ретинол-ассоциированных заболеваний
EA200802135A1 (ru) Фармацевтические композиции антагонистического антитела к cd40
SI2780368T1 (en) INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
AR066660A1 (es) Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
EA200900582A1 (ru) Фармацевтические композиции для профилактики и лечения глазных патологий
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
DE60138137D1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
EA200800291A1 (ru) Способы и композиции для лечения офтальмологических состояний
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
WO2008012367A3 (en) Compositions containing quaternary ammonium compounds
EA200800336A1 (ru) Лечение состояний, связанных с присутствием макромолекулярных агрегатов, в частности глазных расстройств
EA033130B1 (ru) Способы и композиции для улучшения когнитивной функции
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
ATE495164T1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
CL2004001996A1 (es) Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
RU2008117330A (ru) ФАРМАЦЕВТИЧЕСКИ АКТИВНЫЕ ТЕТРАГИДРОПИРРОЛО[1,2-b]ИЗОТИАЗОЛ-1, 1-ДИОКСИДЫ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties